Stockhead on MSN12h
Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drug
Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...
Hosted on MSN16h
Dimerix posts modest gain as first Japanese payment for DMX-200 lands
Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...
Stockhead on MSN15h
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...
TipRanks on MSN1d
Dimerix Limited Announces Quotation of New Securities on ASX
Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...
Petra Capital Reaffirms Their Buy Rating on Dimerix Limited (DXB)
In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...
Stockhead on MSN7d
Health Check: More, please! When record results are not good enough for expectant investors
Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...
Stockhead on MSN13d
Middle East healthcare expansion opens doors for ASX stocks
The Middle East healthcare sector is undergoing rapid expansion presenting opportunities for ASX-listed companies.
Stockhead on MSN20d
ASX healthcare leaders wear many hats in interconnected sector
Dr Nina Webster is the CEO and managing director of Dimerix (ASX:DXB), which in mid-CY25 is due to report the second interim results of its ACTION3 global phase III trial of lead drug DMX-200 to treat ...
The Australian Financial Review4d
Dimerix Limited
Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.